Latest Period
n/a
Security Snapshot
Alnylam Pharmaceuticals Inc - Common Stock Institutional Ownership
CUSIP: 02043Q107
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
Shares (Excl. Options)
Price
$330.87
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Shares outstanding
- 130,175,523
- SEC-reported price per share
- $330.87
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- 02043Q107 - Alnylam Pharmaceuticals Inc - Common Stock is tracked under CUSIP 02043Q107.
- Latest finished 13F holder period is not available.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 4 to 23 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $6,723,054,234 to $173,230,438.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
02043Q107
Latest holder period
n/a
13F holders
13D/G owners
1
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 02043Q107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
02043Q107
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 10% | 13,056,605 | The Vanguard Group | 31 Mar 2025 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
n/a
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 561,669 | $173,230,438 | $330.87 | 23 | |
| 2025 Q4 | 16,906,964 | $6,723,054,234 | +$106,439,276 | $397.65 | 4 |
| 2024 Q3 | 3,468,315 | $953,890,674 | -$18,295,271 | $275.03 | 1 |
| 2024 Q2 | 13,082,499 | $3,179,047,257 | +$210,466,917 | $243.00 | 2 |
| 2024 Q1 | 12,216,380 | $1,825,737,990 | +$86,189,757 | $149.45 | 2 |
| 2023 Q4 | 11,639,667 | $2,227,948,658 | $191.41 | 2 |